Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Neuropathology and Experimental Neurology

• Publication date

  2012-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/NEN.0b013e31825018f7PMID 22487856PMCID PMC3560290
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plaques.

  2019cited by this paper
• Striatal Amyloid Plaque Density Predicts Braak Neurofibrillary Stage and Clinicopathological Alzheimer's Disease: Implications for Amyloid Imaging

  2012cited by this paper
• Preclinical AD Workgroup staging: pathological correlates and potential challenges.

  2012influential reference
• Post‐mortem findings in 10 patients with presumed normal‐pressure hydrocephalus and review of the literature

  2012cited by this paper
• Neuropathology and general autopsy findings in nondemented aged subjects.

  2012cited by this paper
• Erratum: Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155

  2011cited by this paper
• Hippocampal sclerosis in advanced age: clinical and pathological features.

  2011cited by this paper
• Brain Oligomeric &bgr;-Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice

  2011cited by this paper
• Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease

  2011cited by this paper
• Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies

  2011cited by this paper
• The role of β-amyloid peptide in neurodegenerative diseases.

  2011cited by this paper
• Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease

  2011cited by this paper
• The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

  2011cited by this paper
• Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

  2011influential reference
• National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

  2011cited by this paper
• Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.

  2011cited by this paper
• Hippocampal Sclerosis in the Elderly: Genetic and Pathologic Findings, Some Mimicking Alzheimer Disease Clinically

  2011cited by this paper
• Targeting Oligomers in Neurodegenerative Disorders: Lessons from α-Synuclein, Tau, and Amyloid-β Peptide

  2011cited by this paper
• Cerebral amyloid angiopathy pathology and cognitive domains in older persons

  2011cited by this paper
• Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions

  2011cited by this paper
• Alzheimer Disease Pathology in Subjects Without Dementia in 2 Studies of Aging: The Nun Study and the Adult Changes in Thought Study

  2011cited by this paper
• Counting dementia: There is no one “best” way

  2011cited by this paper
• Resolving controversies on the path to Alzheimer's therapeutics

  2011cited by this paper
• Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

  2011cited by this paper
• Stages of granulovacuolar degeneration: their relation to Alzheimer’s disease and chronic stress response

  2011cited by this paper
• Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles*

  2011cited by this paper
• Ecology of the aging human brain.

  2011cited by this paper
• Operationalizing diagnostic criteria for Alzheimer's disease and other age‐related cognitive impairment—Part 2

  2011cited by this paper
• Brain Oligomeric A -Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice

  2011cited by this paper
• “End-Stage” Neurofibrillary Tangle Pathology in Preclinical Alzheimer's Disease: Fact or Fiction?

  2011influential reference
• Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau)

  2011cited by this paper
• Neuropathology and Amyloid-β Spectrum in a Bapineuzumab Immunotherapy Recipient

  2011cited by this paper
• Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States

  2011cited by this paper
• Diagnosing dementia in the oldest-old.

  2011cited by this paper
• S3‐03‐05: Transmission and Spreading of Tauopathy in Transgenic Mouse Brain

  2011cited by this paper
• Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

  2011cited by this paper
• The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics

  2011cited by this paper
• TAR-DNA binding protein-43 and alterations in the hippocampus

  2011cited by this paper
• The pathological process underlying Alzheimer’s disease in individuals under thirty

  2011influential reference
• Brain microbleeds and Alzheimer's disease: innocent observation or key player?

  2011cited by this paper
• Scientific Truth or False Hope? Understanding Alzheimer's Disease from an Aging Perspective

  2011cited by this paper
• Describing the Dying Days of “Alzheimer's Disease”

  2011cited by this paper
• Age, Alzheimer's disease and dementia in the Baltimore Longitudinal Study of Ageing.

  2010cited by this paper
• Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old

  2010cited by this paper
• The genetics of Alzheimer disease: back to the future.

  2010cited by this paper
• Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis

  2010cited by this paper
• Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation.

  2010cited by this paper
• Causes versus effects: the increasing complexities of Alzheimer’s disease pathogenesis

  2010cited by this paper
• Modeling the Association between 43 Different Clinical and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort of Elderly Persons

  2010cited by this paper
• Caspase activation precedes and leads to tangles

  2010cited by this paper
• Neuropathological Associates of Multiple Cognitive Functions in Two Community-Based Cohorts of Older Adults

  2010cited by this paper
• Higher Soluble Amyloid β Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease

  2010cited by this paper
• Low sensitivity in clinical diagnoses of dementia with Lewy bodies

  2010cited by this paper
• Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

  2010cited by this paper
• Brain Aging in the Oldest-Old

  2010cited by this paper
• Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

  2010cited by this paper
• Neurodegenerative basis of age-related cognitive decline

  2010cited by this paper
• γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C

  2010cited by this paper
• A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

  2010cited by this paper
• Dementia incidence continues to increase with age in the oldest old: The 90+ study

  2010cited by this paper
• A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE

  2010cited by this paper
• Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia

  2010cited by this paper
• Reimagining Alzheimer's Disease—An Age-Based Hypothesis

  2010cited by this paper
• Prevalence of dementia disorders in the oldest-old: an autopsy study

  2010cited by this paper
• Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD.

  2010cited by this paper
• The Neuropathology of Older Persons with and Without Dementia from Community versus Clinic Cohorts

  2009cited by this paper
• Classification and basic pathology of Alzheimer disease

  2009cited by this paper
• AD vaccines: conclusions and future directions.

  2009cited by this paper
• Epidemiological Pathology of Dementia: Attributable-Risks at Death in the Medical Research Council Cognitive Function and Ageing Study

  2009cited by this paper
• Propagation of Tau Misfolding from the Outside to the Inside of a Cell*

  2009cited by this paper
• Use of Genetic Variation as Biomarkers for Alzheimer's Disease

  2009cited by this paper
• Neuropathological Correlates of Dementia in Over-80-Year-Old Brain Donors from the Population-Based Cambridge City over-75s Cohort (CC75C) Study

  2009cited by this paper
• Neuropathology-Based Risk Scoring for Dementia Diagnosis in the Elderly

  2009cited by this paper
• Pathological substrates of cognitive decline in Alzheimer's disease.

  2009cited by this paper
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

  2009cited by this paper
• Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update

  2009cited by this paper
• Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction

  2009cited by this paper
• Brains With Medial Temporal Lobe Neurofibrillary Tangles But No Neuritic Amyloid Plaques Are a Diagnostic Dilemma But May Have Pathogenetic Aspects Distinct From Alzheimer Disease

  2009cited by this paper
• Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment.

  2009cited by this paper
• Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?

  2009cited by this paper
• Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship

  2009influential reference
• Does Alzheimer's disease begin in the brainstem?

  2009cited by this paper
• Correlation of Clinical Features With Argyrophilic Grains at Autopsy

  2009cited by this paper
• Transmission and spreading of tauopathy in transgenic mouse brain

  2009cited by this paper
• Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition

  2009cited by this paper
• Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

  2009cited by this paper
• Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

  2009cited by this paper
• Is there a neuropathology difference between mild cognitive impairment and dementia?

  2009cited by this paper
• Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury

  2009cited by this paper
• Age, neuropathology, and dementia.

  2009cited by this paper
• Oskar Fischer and the study of dementia

  2008cited by this paper
• Hyperphosphorylated Tau is a Cause of Neuronal Dysfunction in Tauopathy

  2008cited by this paper
• Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype

  2008cited by this paper
• Amyloid-beta immunisation for Alzheimer's disease.

  2008cited by this paper
• Role of the neuropathology of Alzheimer disease in dementia in the oldest-old.

  2008cited by this paper
• Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.

  2008cited by this paper
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008cited by this paper
• MRI correlates of neurofibrillary tangle pathology at autopsy

  2008cited by this paper
• Neuropathology of Alzheimer's disease.

  2008cited by this paper

• The 2024 NIA-AA biological definition of Alzheimer's disease: linking biomarkers to clinical practice.

  2026cites this paper
• Gray matter microstructure from in vivo diffusion magnetic resonance imaging reflects post mortem neuropathology severity and clinical progression of Alzheimer's disease

  2026cites this paper
• The effect of Alzheimer’s biomarker positivity on neuropsychological networks

  2026cites this paper
• Proteomic remodelling of the neurofibrillary tangle from “PART” to advanced Alzheimer’s disease

  2026cites this paper
• Graphical modeling of cortical tau pathology topography for its subtyping in Alzheimer’s disease

  2026cites this paper
• Fluorescent Labeling Methods for Brain Structure Research

  2026cites this paper
• Medial temporal lobe atrophy is associated with age and pathologies, especially small vessel disease

  2026cites this paper
• Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer's disease and related dementias in a multi-site autopsy cohort

  2026cites this paper
• Spatial patterns of tau accumulation across the Alzheimer's disease spectrum

  2026cites this paper
• Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding

  2026cites this paper
• Antimicrobial peptides act as a component of brain immunity against microbes in Alzheimer's disease.

  2026cites this paper
• Procoagulant Extracellular Vesicles Increase Neuronal Tau expression, Metabolism and Processing Through Tissue Factor and Protease Activated Receptor 2

  2026cites this paper
• Heat Therapy: Targeting Health, Disease, and Disability

  2026cites this paper
• Detecting early memory changes in preclinical Alzheimer's disease using TabCAT favorites test: Data from the European Prevention of Alzheimer's Disease (EPAD) cohort

  2026cites this paper
• Machine learning prediction of dementia conversion in mild cognitive impairment: A two- to six-year follow-up study

  2026cites this paper
• The monoaminergic systems as drivers of Alzheimer's disease pathophysiology and symptomatology.

  2026cites this paper
• Inflammatory mechanisms underlying early Alzheimer's disease pathology: evidence from the aging rhesus macaque brain.

  2026cites this paper
• Equity and Transportability of Plasma ATN Phenotypes in a Population-Representative U.S. Aging Cohort

  2026cites this paper
• Comparing Gallyas and AT8 staining for quantification of tau pathology in subregions of the human hippocampus.

  2026cites this paper
• Spatiotemporal dynamics of tau pathology and neurodegeneration in Medial Temporal Lobe (MTL) subregions across alzheimer's disease progression: A multimodal imaging study using second-generation tracer [18F]MK-6240.

  2026cites this paper
• Identifying early changes in imaging, plasma, and digital cognitive biomarkers that correspond to Alzheimer's disease pathology in the presence of autopsy‐confirmed co‐pathologies

  2026cites this paper
• Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology

  2025cites this paper
• The tale of donanemab: God is in the details

  2025cites this paper
• Air Pollution as a Key Risk Factor for Alzheimer’s Disease: A Comprehensive Review

  2025cites this paper
• Divergent effects of age on imaging‐based ATN biomarkers and cognition in Alzheimer's disease

  2025cites this paper
• Cognitive impairment and p‐tau217 are high in a vascular patient cohort

  2025cites this paper
• Deterioration of Lexical Processing in Older Chinese Adults With Alzheimer's Disease: Insights From Reading Chinese Compounds.

  2025cites this paper
• AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer’s disease

  2025cites this paper
• Impact of a White Matter Reference Region on the Relationship between Florbetapir PET Measurements of Amyloid Plaque Deposition and Measurements of Cognitive Decline

  2025cites this paper
• Regional tau PET patterns predict prospective domain-specific cognitive decline in early symptomatic Alzheimer’s disease

  2025cites this paper
• Twenty years of therapeutic development in tauopathy mouse models: a scoping review

  2025cites this paper
• Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease

  2025cites this paper
• Multi-tissue Methylation Analysis of Alzheimer’s Disease: Insights into Pathways, Modules, and Key Genes

  2025cites this paper
• Impact of hippocampal α‐synuclein oligomers on cognitive trajectory in patients with dementia with Lewy bodies

  2025cites this paper
• Achieving detailed medial temporal lobe segmentation with upsampled isotropic training from implicit neural representation

  2025cites this paper
• Primary age-related tauopathy

  2025influential citation
• Pathological biomarkers for Alzheimer's disease in cognitively unimpaired individuals are not associated with cognitive decline at two-year follow-up.

  2025cites this paper
• Neural Metabolic Networks: Key Elements of Healthy Brain Function

  2025cites this paper
• Dizziness and neuro-otologic findings in neurodegenerative disorders: a review

  2025cites this paper
• Modeling Alzheimer’s Disease: A Review of Gene-Modified and Induced Animal Models, Complex Cell Culture Models, and Computational Modeling

  2025cites this paper
• Microstructural assessment of the locus coeruleus–entorhinal cortex pathway and association with ATN markers in cognitive impairment

  2025cites this paper
• Celebrating 40 years of the University of Kentucky Alzheimer's Disease Research Center

  2025cites this paper
• Entorhinal tau impairs short-term memory binding in preclinical Alzheimer’s disease

  2025cites this paper
• Porphyromonas gingivalis-Lipopolysaccharide Induced Caspase-4 Dependent Noncanonical Inflammasome Activation Drives Alzheimer’s Disease Pathologies

  2025cites this paper
• Molecular signatures of regional vulnerability to tauopathy in excitatory cortical neurons

  2025cites this paper
• Molecular subtyping based on hippocampal cryptic exon burden reveals proteome-wide changes associated with TDP-43 pathology across the spectrum of LATE and Alzheimer’s Disease

  2025cites this paper
• The Effects of Mindfulness Meditation on Mechanisms of Attentional Control in Young and Older Adults: A Preregistered Eye Tracking Study

  2025cites this paper
• Performance of novel tau antibodies across multiple modalities for Alzheimer's disease assessment

  2025cites this paper
• The Key Flavor Substance in Zanthoxylum Preventing Alzheimer's Disease through Insulin Signaling.

  2025cites this paper
• Baseline and longitudinal changes in cortical thickness and hippocampal volume predict cognitive decline

  2025cites this paper
• Cognitive and neuropsychological trajectories in patients with mixed neurodegenerative pathologies

  2025cites this paper
• An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer's disease

  2025cites this paper
• The first 25 years of the Northwestern University SuperAging Program

  2025cites this paper
• Bridging the molecular and clinical aspects of resveratrol in Alzheimer’s disease: a review

  2025cites this paper
• Impaired MAPT/tau-secretory lysosomes are linked to cognitive vulnerability in Alzheimer patients

  2025cites this paper
• Rodent models of Alzheimer's disease: critical analysis of current hypotheses and pathways for future research.

  2025cites this paper
• Neuronal Death and Biomolecular Condensates: Are There Any New Treatment Options for Alzheimer’s Disease?

  2025cites this paper
• Preclinical detection of Alzheimer’s disease pathology using conceptual discrimination abilities

  2025cites this paper
• Prognostic Value of A/T/N Biomarkers

  2025cites this paper
• AAV-mediated peripheral scFv's administration to reduce cerebral tau in adult P301S transgenic mice: Mono-vs. combination therapy

  2025cites this paper
• Design and application of a Tau seed amplification assay for screening inhibitors of Tau seeding

  2025cites this paper
• Spatiotemporal patterns of amyloid deposition as prognostic markers of Alzheimer's disease.

  2025cites this paper
• Photobiomodulation therapy increases neural stem cell pool in aged 3xTg-AD mice

  2025cites this paper
• Risk of Alzheimer's disease in Down syndrome: Insights gained by multi‐omics

  2025cites this paper
• Research models to study lewy body dementia

  2025cites this paper
• Chronic Imaging of Dendritic Spine Morphology in Transgenic Mice of the 5xFAD-M Hybrid Strain, a Model of Alzheimer’s Disease

  2025cites this paper
• Comparative analysis of brain-derived tau oligomer interactomes in Alzheimer's disease, non-demented with Alzheimer's neuropathology, and primary age-related tauopathy: Implications for neurodegeneration and cognitive resilience

  2025cites this paper
• Do microglia metabolize fructose in Alzheimer’s disease?

  2025cites this paper
• Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory

  2025cites this paper
• Biofluid-based staging of Alzheimer’s disease

  2025cites this paper
• AAV-mediated peripheral single chain variable fragments’ administration to reduce cerebral tau in adult P301S transgenic mice: mono- vs combination therapy

  2025cites this paper
• Tau PET Imaging With [18 F]MK‐6240: Limited Affinity for Primary Tauopathies and High Specificity for Alzheimer's Disease

  2025cites this paper
• TDP43 is a newly identified substrate for PS1, enhancing the expression of APP following cleavage

  2025cites this paper
• Brain activation in older adults during odor identification is related to ApoE, t-tau/Aβ1-42, and hippocampal volume.

  2025cites this paper
• The tau isoform 1N4R confers vulnerability of MAPT knockout human iPSC‐derived neurons to amyloid beta and phosphorylated tau‐induced neuronal dysfunction

  2025cites this paper
• Endogenously generated Dutch-type Aβ nonfibrillar aggregates dysregulate presynaptic neurotransmission in the absence of detectable inflammation

  2025cites this paper
• Unraveling the mystery of citrate transporters in Alzheimer's disease: An updated review.

  2025cites this paper
• Effects of preemptive acupuncture on cognitive function of older patients after hip replacement: a randomized controlled trial

  2025cites this paper
• Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease

  2025cites this paper
• The many roads to dementia: a systems view of Alzheimer's disease

  2025cites this paper
• Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum.

  2025cites this paper
• Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force

  2025cites this paper
• Colorimetric detection of amyloid-β oligomers using aptamer-templated DNA-Ag/Pt nanoclusters with peroxidase-like activity

  2025cites this paper
• Lower locus coeruleus integrity is associated with diminished practice effects in clinically unimpaired older individuals.

  2025cites this paper
• Use of magnetic resonance structural imaging to identify disease progression in patients with mild cognitive impairment: A voxel-based morphometry and surface-based morphometry study.

  2025cites this paper
• Hyperphosphorylated tau-based Alzheimer’s Disease drug discovery: Identification of inhibitors of tau aggregation and cytotoxicity

  2025cites this paper
• Exploring the pharmacological mechanism of Bu-Wang San on Alzheimer's disease through multiple GEO datasets of the human hippocampus, network pharmacology, and metabolomics based on GC-MS and UPLC-Q/TOF-MS.

  2025cites this paper
• hiPSC-neurons recapitulate the subtype-specific cell intrinsic nature of susceptibility to neurodegenerative disease-relevant aggregation

  2025cites this paper
• A Narrative Review Evaluating Diet and Exercise as Complementary Medicine for the Management of Alzheimer’s Disease

  2025cites this paper
• CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures.

  2025cites this paper
• Gray matter microstructure from in-vivo diffusion MRI reflects post-mortem neuropathology severity and clinical progression of Alzheimer’s disease

  2025cites this paper
• Brain tau PET-based identification and characterization of subpopulations in patients with Alzheimer’s disease using deep learning-derived saliency maps

  2025cites this paper
• Telomere-driven senescence accelerates tau pathology, neuroinflammation and neurodegeneration in a tauopathy mouse model

  2025cites this paper
• The Neurofibrillary Tangle Maturity Scale: A Novel Framework for Tangle Pathology Evaluation in Alzheimer’s Disease

  2025cites this paper
• Small‐diffusible aggregates, plaques, tangles, and dynamic equilibria: Untangling Alzheimer's disease

  2025cites this paper
• Immunoelectron microscopy and biochemical studies using three anti-tau antibodies in human brains: associations between pTau and ribosomes

  2025cites this paper
• Ante-mortem cognitive trajectories associated with Aβ and tau biomarker profiles in older adults with cerebrovascular disease: a longitudinal cohort study

  2025cites this paper
• Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers

  2025cites this paper
• Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex

  2025cites this paper
• Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease

  2025cites this paper